Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

For Consumers

Tentative approval of lamivudine/zidovudine copackaged with abacavir sulfate

The Food and Drug Administration granted tentative approval on July 26, 2006 for lamivudine/zidovudine tablets, co-packaged with abacavir sulfate tablets, for treatment of HIV, manufactured by Aurobindo Pharma Limited Inc., of Hyderabad, India.

The lamivudine/zidovudine combination is a generic formulation of the approved combination product, Combivir, manufactured by GlaxoSmithKline, which combines the two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in a single tablet. Abacavir sulfate, which is also an NRTI, is a generic formulation of the approved product, Ziagen, also manufactured by GlaxoSmithKline.

The application was reviewed under expedited review provisions for the President's Emergency Plan for AIDS Relief (PEPFAR).

"Tentative Approval" means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, though it may not be marketed in the U.S. because of existing patents and/or exclusivity rights. Tentative approval, however, does make the product eligible for consideration for purchase under the PEPFAR program.

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

Page Last Updated: 08/05/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.